The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Abstract
3,1232,680MetricsTotal Downloads3,123Last 6 Months470Last 12 Months1,013Total Citations2,680Last 6 Months51Last 12 Months112View all metrics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Prevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citation(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
Items 201–300 of 344
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
The prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 341
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Self-citationZhao, X., Weir, B. A., LaFramboise, T., Lin, M., Beroukhim, R., Garraway, L., Beheshti, J., Lee, J. C., Naoki, K., Richards, W. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4603 · Cited by 337
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 335
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Barault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J., Lièvre, A., Cortet, M., Bouvier, A., Rat, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23388 · Cited by 331
Glioma Stem Cells: A Midterm Exam
Stiles, C. D., & Rowitch, D. H. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.031 · Cited by 330
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
Koren, S., Reavie, L., Couto, J. P., De Silva, D., Stadler, M. B., Roloff, T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015) · Nature · doi:10.1038/nature14669 · Cited by 327
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Lindhurst, M. J., Parker, V. E. R., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2332 · Cited by 325
O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J., O'Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., Chan, A. T., Engelman, J. A., Kraft, P., Cantley, L. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6544 · Cited by 323
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 321
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity
Sun, Y., Xu, Y., Roy, K., & Price, B. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01382-07 · Cited by 319
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Ciruelos Gil, E. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.004 · Cited by 314
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
Dillon, R. L., White, D. E., & Muller, W. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210202 · Cited by 311
AKT Inhibition in Solid Tumors With AKT1 Mutations
Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Pérez-Fidalgo, J. A., Mita, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 311
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
Self-citationMcCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Xing, M. (2010) · Thyroid · doi:10.1089/thy.2010.1646 · Cited by 305
Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum
Keppler‐Noreuil, K. M., Sapp, J. C., Lindhurst, M. J., Parker, V. E. R., Blumhorst, C., Darling, T., Tosi, L. L., Huson, S. M., Whitehouse, R. W., Jakkula, E., et al. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36552 · Cited by 305
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang, S., Garcia-Echeverria, C., & Maira, S.-M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905152106 · Cited by 303
Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability
Xu, N., Lao, Y., Zhang, Y., & Gillespie, D. A. (2012) · Journal of Oncology · doi:10.1155/2012/951724 · Cited by 302
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedImplementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
Translating insights from the cancer genome into clinical practice
Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 300
Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
Vadas, O., Burke, J. E., Zhang, X., Berndt, A., & Williams, R. L. (2011) · Science Signaling · doi:10.1126/scisignal.2002165 · Cited by 299
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
Oxnard, G. R., Binder, A., & Jänne, P. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9829 · Cited by 299
Genomics and the Continuum of Cancer Care
McDermott, U., Downing, J. R., & Stratton, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0907178 · Cited by 299
Emerging common themes in regulation of PIKKs and PI3Ks
Lempiäinen, H., & Halazonetis, T. D. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.281 · Cited by 298
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Self-citationPrenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.-H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908444106 · Cited by 293
Self-citationPérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Berndt, A., Miller, S., Williams, O., Le, D. D., Houseman, B. T., Pacold, J. I., Gorrec, F., Hon, W.-C., Ren, P., Liu, Y., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.293 · Cited by 292
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
Self-citationCancer-Associated PIK3CA Mutations in Overgrowth Disorders
Madsen, R. R., Vanhaesebroeck, B., & Semple, R. K. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.003 · Cited by 276
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
McConechy, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L. M., Wiegand, K. C., McAlpine, J. N., Shah, S. P., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.107 · Cited by 288
Protein Kinases and Phosphatases in the Control of Cell Fate
Bononi, A., Agnoletto, C., De Marchi, E., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., Missiroli, S., Poletti, F., Rimessi, A., et al. (2011) · Enzyme Research · doi:10.4061/2011/329098 · Cited by 285
Cancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Mammalian phosphoinositide kinases and phosphatases
Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., & Suzuki, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.06.001 · Cited by 283
Choi, K. S. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.2.033 · Cited by 282
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease
Burke, J. E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.005 · Cited by 276
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutierrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
PIK3CA mutation status in Japanese lung cancer patients
Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.07.006 · Cited by 273
Carnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
Kharas, M. G., Okabe, R., Ganis, J. J., Gozo, M., Khandan, T., Paktinat, M., Gilliland, D. G., & Gritsman, K. (2010) · Blood · doi:10.1182/blood-2009-06-229443 · Cited by 272
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 267
Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510772103 · Cited by 267
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer
Coppedè, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.943 · Cited by 264
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 264
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
Smith, T. M., Gilliland, K., Clawson, G. A., & Thiboutot, D. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701155 · Cited by 261
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.189 · Cited by 259
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Loibl, S., von Minckwitz, G., Schneeweiss, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, P., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2402 · Cited by 257
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
Yu, K., Lin, C.-C. J., Hatcher, A., Lozzi, B., Kong, K., Huang-Hobbs, E., Cheng, Y.-T., Beechar, V. B., Zhu, W., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1952-2 · Cited by 253
Burger, M. T., Pecchi, S., Wagman, A., Ni, Z.-J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200156t · Cited by 252
BAD: undertaker by night, candyman by day
Danial, N. N. (2008) · Oncogene · doi:10.1038/onc.2009.44 · Cited by 252
Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells
Lim, K.-H., O'Hayer, K., Adam, S. J., Kendall, S. D., Campbell, P. M., Der, C. J., & Counter, C. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.10.023 · Cited by 250
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0976 · Cited by 228
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
DeBerardinis, R. J., Lum, J. J., & Thompson, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608372200 · Cited by 221
Lombardo, Y., Scopelliti, A., Cammareri, P., Todaro, M., Iovino, F., Ricci–Vitiani, L., Gulotta, G., Dieli, F., de Maria, R., & Stassi, G. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.005 · Cited by 222
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia
Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., & Ellenson, L. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1375 · Cited by 218
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214
Metadata
- Authors
- Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Venue
- Science
- Published
- 2004-04-23
- Volume
- 304
- Issue
- 5670
- Pages
- 554-554
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2129172946
- Cited by
- 3,437
- References
- 4
- FWCI
- 43.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.